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Purpose: Effective treatment options for negative symptoms and cognitive impairment in
patients with schizophrenia are still to be developed. The present study was to examine
potential beneﬁts of repetitive transcranial magnetic stimulation (rTMS) to improve negative
symptoms and cognition in this patient population.
Methods: The study was a 4-week, randomized, double-blind sham-controlled trial. Patients
with schizophrenia were treated with adjunctive 20-Hz rTMS for 4 weeks or sham condition
to the left dorsolateral prefrontal cortex (DLPFC). Negative symptoms were measured using
the Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative
symptom scale (PANSS) negative subscale at baseline and week 4. Cognitive function was
measured using the MATRICS Consensus Cognitive Battery (MCCB) at the same two time
points. In addition, possible moderators for rTMS treatment efﬁcacy were explored.
Results: Sixty patients (33 in the treatment group, 27 in the sham group) completed the
study. There was a signiﬁcant decrease in negative symptoms after 4-week rTMS
treatment as measured by the SANS total score and the PANSS negative symptom
subscale score. However, there was no signiﬁcant improvement in cognition with
rTMS treatment. Stepwise multiple linear regression analysis suggested that the baseline
severity of positive symptoms may predict poorer improvement in negative symptoms at
week 4.
Conclusion: Twenty-Hz rTMS stimulation over left DLPFC as an adjunctive treatment
might be beneﬁcial in improving negative symptoms of schizophrenia. Future studies with
a longer treatment duration and a larger sample size are needed.
Clinical trial ID: NCT01940939.
Keywords: schizophrenia, negative symptoms, cognitive impairment, repetitive transcranial
magnetic stimulation, rTMS, MCCB
Introduction
Schizophrenia is a severe and lifelong neuropsychiatric condition that affects
approximately 1% of the world’s population.1,2 Both negative symptoms and
cognitive impairment are among the core features of schizophrenia; both types of
symptoms are important predictors for real life functioning.3 Despite enormous
effort over the past several decades, effective treatment options to improve negative
symptoms or cognition are still not available.4–7
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Repetitive transcranial magnetic stimulation (rTMS) is
a relatively safe and non-invasive method that uses alter-
nating magnetic ﬁelds to induce an electric current in the
underlying brain tissue.8 Studies have demonstrated that
that high-frequency rTMS may be able to increase cortical
excitability and modulate dopamine release in certain
brain areas, including the prefrontal cortex.9–11 As nega-
tive symptoms and cognitive deﬁcits in schizophrenia may
be related to a lack of dopamine at the prefrontal cortex
and hypofrontality.12,13 rTMS may have beneﬁcial effects
to improve these two types of symptoms.9,14
Recently, meta-analyses on rTMS treatment for nega-
tive symptoms of schizophrenia suggest an effect size of
0.27–0.53.15–17 In addition, high-frequency rTMS may
enhance cognitive function in patients with schizophrenia.
An early study found that active high-frequency rTMS
applied to the dorsolateral prefrontal cortex (DLPFC) in
healthy volunteers signiﬁcantly increased gamma oscilla-
tions generated during the N-back conditions with the
greatest cognitive demand.18 Only a few studies focused
on the effects of rTMS on cognition impairment of schizo-
phrenia. One study suggested that rTMS could improve
working memory in schizophrenia, whereas another study
had a negative outcome.19,20
Several important questions remain to be addressed
regarding the use of rTMS treatment in patients with
schizophrenia: rTMS stimulus frequency, motor threshold
(MT), stimulus location, total stimulus strength, duration
of stimulus, baseline psychopathology, duration of illness
as well as the type of outcome measures used. The present
study was a 4-week, randomized, double-blind sham-
controlled trial. Patients with schizophrenia were treated
with adjunctive 20-Hz rTMS for 4 weeks or sham condi-
tion to the left DLPFC. The primary hypothesis was that
rTMS treatment can improve both negative symptoms and
cognitive impairment at week 4. In addition, possible
moderators for rTMS treatment efﬁcacy were explored.
Several important questions remain to be addressed
regarding the use of rTMS treatment in patients with
schizophrenia: rTMS stimulus frequency, motor threshold
(MT), stimulus location, total stimulus strength, duration
of stimulus, baseline psychopathology, duration of illness
as well as the type of outcome measures used. The present
study was a 4-week, randomized, double-blind sham-
controlled trial. Patients with schizophrenia were treated
with adjunctive 20-Hz rTMS for 4 weeks or sham condi-
tion to the left DLPFC. The primary hypothesis was that
rTMS treatment can improve both negative symptoms and
cognitive impairment at week 4. In addition, possible
moderators for rTMS treatment efﬁcacy were explored.
Methods
The study was undertaken in Shanghai Mental Health
Center, Shanghai Jiao Tong University School of
Medicine from 2013 to 2014. The trial has been registered
at http://www.clinicaltrials.gov (NCT01940939), and the
trial protocol has been published. No additional unpub-
lished data are available.
Participants
Potential subjects were recruited from the inpatient units
of Shanghai Mental Health Center. Individuals eligible for
the study were adults aged 20–60 years who had
a diagnosis of schizophrenia according to the Diagnostic
and Statistical Manual of Mental Disorders, 4th edition,
text revision (DSM-IV-TR) criteria; the diagnosis was
further conﬁrmed using the Structured Clinical Interview
for DSM-IV-TR, Clinical Trials Version. Patients had to be
on a stable dose of antipsychotic medication for at least 1
month before the study enrollment. Benzodiazepines can
be used temporarily for no longer than 7 days if patients
complained about sleeplessness at night, and stopped 24
h before the cognitive testing and clinical assessment. In
addition, patients had to meet the following clinical cri-
teria: the negative symptoms subscale score of the Positive
and Negative Syndrome Scale (PANSS) 20 or more.
Exclusion criteria included: a current DSM-IV-TR axis
I disorder other than schizophrenia, a history of epilepsy or
seizure; signiﬁcant or unstable neurologic disorder; cardiac
pacemaker; previous brain injury or surgery; any metal
clips, plates, or other metal items in the head; or substance
dependency; or ECT within 3 months. All participants
provided written informed consent.
Clinical measures
Clinical measures included: the PANSS21 and the Scale for
the Assessment of Negative Symptoms (SANS),22 and the
Clinical Global Impressions (CGI) score.23 Cognitive func-
tion was assessed using the MATRICS Consensus Cognitive
Battery (MCCB) in Chinese Version.24 The MCCB in
Chinese Version includes 9 tasks across 7 domains, and
a composite score, including Processing Speed (Brief
Assessment of Cognition in Schizophrenia Symbol Coding,
Animal Fluency, Trails A), Attention (Continuous
Performance Test), Working Memory (WMS-III Spatial
Span), Verbal Learning (Hopkins Verbal Learning Test –
Zhuo et al Dovepress
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Revised), Visual Learning (Brief Visuospatial Memory
Test – Revised), Problem Solving (Neuropsychological
Assessment Battery), and Social Cognition (Mayer-Salovey-
Caruso Emotional Intelligence Test). The Letter-Number
Span Test (LNS) was excluded from the original MCCB
because there is no corresponding alphabet in Chinese.
Total administration time is 60–90 min. MCCB was used at
baseline and within 24 h after rTMS intervention. To avoid
practice effects, version Awas taken at baseline and version
B for retest at the end of intervention.
rTMS protocol
Participants received 20 treatment sessions on consecutive
weekdays. Patients were randomly assigned to receive
either 20 Hz rTMS applied to the left DLPFC (EEG
International 10–20 system, F3-electrode) or the sham
condition. High-frequency rTMS has been shown to
enhance gamma-aminobutyric acid (GABA)-mediated
inhibitory neurotransmission with increased stimulation
frequency, with the maximal inhibitory effect achieved at
20 Hz.25 The F3-position used in our study corresponds to
Brodmann areas 8, 9, and 46 in the medial frontal
gyrus.26–28 The rTMS treatment had an intensity of 90%
of the individual resting motor threshold (MT) and 2,000
stimuli (100 trains with 20 stimuli per train, 9 s intertrain
interval) per session. Stimuli were applied using a MagPro
X100 stimulator (MagVenture) and a standard butterﬂy
coil (MFC-B65). rTMS was performed in accordance
with the recommendations by the International Workshop
on the Safety of Repetitive Transcranial Magnetic
Stimulation.29 Sham rTMS stimulation was delivered
using the same stimulation parameters and at the same
site as in active treatment, but the coil was ﬂipped 180°
around its main axis so that the thickness of the integrated
cooling system of the coil between the skull and the coil
center was 53 mm. This method produces sound and some
somatic sensation (eg, contraction of scalp muscles) simi-
lar to those of active stimulation, but the resulting increase
in spatial distance translated into a reduction in stimulation
intensity of 80% (MagVenture).30
Data analysis
Data were analyzed using SPSS 22.0 (IBM Corporation,
Armonk, NY, USA). Baseline differences in demographic
and clinical variables between the two treatment groups
were examined using independent t-test and chi-squared
test. Repeated measures ANOVA was performed for the
primary outcome measures (negative symptoms,
cognition) with group condition (active treatment vs
sham) as the between-subject factor and time (baseline, 4
weeks) as the within-subject factor. Pearson correlation
analysis was used to examine the relationship among vari-
ables. Stepwise multiple linear regression analysis was
used to identify potential predictors for the primary out-
come measures.
Ethics statement
The research protocol was approved by the Institutional
Review Board of Shanghai Mental Health Center
(2013–04). This study was conducted in accordance with
the 1964 Declaration of Helsinki and its later amendments
or comparable ethical standards. The subjects were assured
of the following: their participation was voluntary, they
could withdraw at any time without facing any negative
consequences, their anonymity would be protected, and the
data obtained would not be used for purposes other than the
present research. All participants provided their written
informed consent. The research purpose and guarantee to
protect the privacy of the subjects were explained verbally
as well as in written form to the participants by the doctor.
Results
Demographic and clinical characteristics
Eighty-one patients were screened, and 70 were rando-
mized to either active treatment or sham condition.
Thirty-three patients completed 4-week active treatment,
and 27 completed the sham treatment. Seven patients
withdrew from the study because of the time commitment
whereas three patients dropped out because of
a diminished interest in the study (Figure 1). Three
patients in the sham group and four in the active group
reported a transient headache, and one in the active group
reported dizziness in the initial period. After giving com-
fort and reducing the initial intensity of stimulation, the
symptoms were signiﬁcantly reduced. No other adverse
events were observed. Table 1 shows the demographic,
clinical and cognitive characteristic of the two groups.
The two groups did not differ in demographic, clinical
and cognitive characteristics. The numbers of patients on
different antipsychotic drugs for the active treatment
group versus sham groups are as follows: olanzapine 6/
6, risperidone 6/5, paliperidone 12/10, amisulpride 2/2,
ziprasidone 3/0, clozapine 1/0, quetiapine 1/1 and aripi-
prazole 2/3. Five patients also used mood stabilizer
(valproate 2/3).
Dovepress Zhuo et al
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Negative symptoms and cognitive
function after 4-week treatment
Patients in the active and sham group were classiﬁed as
having a clinical improvement with baseline CGI, SANS
total score, PANSS total score, and the three PANSS sub-
scores (Figure 2). Repeated measures ANOVA revealed
a signiﬁcant group-by-time interaction for SANS total
score (F(1, 59)=5.632, p=0.021), PANSS negative
33 completed treatment
35 allocated to the active rTMS
treatment
35 allocated to the sham rTMS
treatment
70 patients randomised (1:1)
81 patients assessed for
eligibility
27 completed treatment
8 discontinued treatment
2 withdrew consent
3 not compliant
3 lost to follow-up
8 Inclusion or exclusion criteria
not met
3 withdrew consent
11 ineligible
2 discontinued treatment
1 withdrew consent
1 lost to follow-up
Figure 1 The study ﬂow chart.
Abbreviation: rTMS, repetitive transcranial magnetic stimulation.
Table 1 The demographic and clinical characteristic of the two groups
20 Hz (n=33) Sham (n=27) Group comparison
Mean (SD) Mean (SD) t/x2 p
Age (years) 28.97 (7.40) 30.63 (8.25) 0.416 0.521
Education (years) 12.70 (2.54) 12.41 (2.34) 0.244 0.623
Course of illness (years) 7.20 (5.46) 8.11 (5.64) 0.001 0.977
Dose of chlorpromazine equivalents (mg) 400.48 (252.17) 421.93 (209.23) 0.298 0.587
IQ 92.17 (14.25) 95.72 (14.37) 0.100 0.754
PANSS-total 68.15 (5.535) 69.93 (6.528) 1.824 0.182
PANSS-positive 14.61 (3.381) 15.26 (2.669) 0.976 0.327
PANSS-negative 21.70（3.349） 22.63（3.824） 1.323 0.255
PANSS-general 31.85（3.022） 32.04（3.391） 1.212 0.275
SANS 48.09（11.204） 50.33（12.551） 0.405 0.527
CGI 4.88 (0.33) 4.93 (0.55) 2.171 0.146
Gender
Male 22 19 0.094 0.759
Female 11 8
Abbreviations: IQ intelligence quotient; PANSS, Positive and Negative Syndrome Scale; SANS, Scale for the Assessment of Negative Symptoms; CGI, clinical global
impression.
Zhuo et al Dovepress
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subscore (F(1, 59)=8.090, p=0.006), and CGI-S (F(1,59)
=4.436, p=0.040). However, no group-by-time interaction
was found for PANSS total score, PANSS positive score,
and PANSS general score (Table 2).
Though the T scores in some domains (eg, Speed of
Processing, Verbal Learning, Visual Learning, Social
Cognition, and Composite Score) were improved with base-
line after 4-week treatment in both groups (Table 3),
no group-by-time interactions in any domains were found
between the two groups. Even the repeated measures
ANOVA found a trend of group-by-time interactions reﬂect-
ing those patients in the sham group got more improvement
in Composite Score (F(1,59)=3.491, p=0.068) and BACS test
(F(1,59)=3.884, p=0.054) than those in the active group.
Associations between the reduction of
negative symptoms of schizophrenia and
clinical and demographic variables
In both groups, the reduction rate of SANS total score,
PANSS total score, and the three PANSS subscores were
not correlated with demographic variables (age, education,
course of illness, dose of antipsychotic drug or IQ).
Meanwhile, there were no signiﬁcant correlations between
20
0
Weeks after start of rTMS
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Sham group
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Figure 2 Scores for severity of symptoms during the trail. Data appear mean ± SD in blue for active rTMS and in red for sham rTMS.
Notes: Patients in the active rTMS group had a great improvement in SANS total score and PANSS negative subscore after 4-week treatment (A and D). However, there
were no signiﬁcant differences in PANSS total score and positive subscore between the active and sham rTMS group (B and C).
Abbreviation: rTMS, repetitive transcranial magnetic stimulation.
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the T score changes (pre- and post-treatment) of the MCCB
with the reduction rate of the SANS, PANSS total score and
the three PANSS subscores (Pearson correlation).
Stepwise multiple linear regression analysis of the
SANS reduction rate and clinical symptoms showed that
a higher PANSS positive symptoms subscore at baseline
predicts a lower SANS total score reduction rate at week 4
(Table 4). In addition, a higher SANS total score at base-
line seemed to predict a higher SANS total score reduction
at week 4. However, these relationships were not observed
in the sham group.
Discussion
Our study found a signiﬁcant improvement of negative
symptoms as measured by PANSS negative score and
SANS total score after 4 weeks of 20 Hz rTMS over
the left DLPFC compared with sham rTMS. Our results
are consistent with previous studies,31–34 which found
that high-frequency rTMS over the left DLPFC may
lead to improvement in the negative symptoms of
schizophrenia.
The open-label study of Cohen et al35 ﬁrst reported
that 20 Hz rTMS targeting DLPFC reduced the PANSS
negative subscale. However, some follow-up studies
did not alleviate negative symptoms despite several
methodological improvements (eg, double-blind sham-
controlled parallel design and a higher number of
pulses). For instance, Novak et al failed to ﬁnd any
signiﬁcant effect of 20 Hz rTMS (90% MT, 20,000
stimuli) on PANSS negative subscales after a two-
week treatment.36 This may be due to the insufﬁcient
duration, which was recommended in a meta-analysis
to be no less than three weeks.17 Meanwhile, bilateral
20 Hz rTMS (90% MT, 30,000 stimuli) was used in
Barr et al’s study, but no signiﬁcant improvement in
negative symptoms or depressive symptoms were
found.37 It may be insufﬁcient to detect an improve-
ment in negative symptoms after rTMS treatment
because of the relatively small sample size.
Our study also found that patients with less positive
symptoms at baseline tended to have a better response in
negative symptom improvement even though the positive
symptoms did not improve in our study. This suggests that
the severity of existing positive symptoms in patients with
schizophrenia may have an adverse effect on rTMS in the
treatment for negative symptoms. This phenomenon is simi-
lar to that of antipsychotic drugs such as clozapine in the
treatment of refractory schizophrenia.38 Secondly, we foundTa
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that patients with more negative symptoms of baseline
tended to beneﬁt more from rTMS treatment. Our result is
consistent with the ﬁndings from a recent meta-analysis.17
In addition, both patients in the active and sham group
had clinical improvement with baseline CGI, SANS total
score, PANSS total score, and the three PANSS subscores,
which suggested that a placebo effect should be taken into
account. In Shi et al’s meta-analysis,17 a small placebo
effect had been found in the treatment effect of rTMS on
negative symptoms in schizophrenia. However, none of
the scores in the sham group met the criterion for response
(ie a 20% reduction in baseline PANSS negative symptom
score and SANS total score) in our study at the end of
treatment. Similar results were found in the Mogg et al’s
study.39
Dysfunctional oscillations may have a central role in
the pathophysiology of schizophrenia, which may be
caused by the anomalies in the brain’s rhythm-
generating networks of GABA interneurons and cortico-
cortical connections. In patients with schizophrenia, the
abnormalities of beta and gamma-band activity suggest
the cognitive deﬁcits and other symptoms of the
disorder.40 High-frequency rTMS (10–20 Hz) can mod-
ulate gamma oscillatory activity, which may be
a possible avenue for cognitive improvement in this
disorder.41 Although Shi et al suggest that 10 Hz stimu-
lation is probably more effective than 20 Hz in the
treatment of negative symptoms,17 the optimal rTMS
frequency to achieve the maximal therapeutic effect for
cognitive impairment is still to be determined. It has
been suggested that greater stimulation frequency and
a greater number of treatment sessions may result in
greater treatment effects.
Several previous studies have examined rTMS treat-
ment and cognitive function in schizophrenia with incon-
sistent ﬁndings. For example, Mogg39 found that 10 Hz
high-frequency rTMS led to a signiﬁcant improvement in
verbal learning among patients with schizophrenia, while
Schneilder42 did not ﬁnd any signiﬁcant change for the
Wisconsin Card Sorting Test (WCST) among the three
groups of either placebo, 1 Hz low-frequency or 10 Hz
high-frequency rTMS at 110% MT over the left DLPFC.
These studies only reﬂected the change in several
domains but cannot evaluate the comprehensive and
broad improvement of the cognition in schizophrenic
patients. Though the T score in some domains were
improved after 4-week rTMS treatment, unfortunately,
our study found that 20 Hz rTMS had no beneﬁt for
cognitive improvement in the active group relative to
sham group, while there was a trend towards suggesting
those patients in the sham group improved more than
those in the active group in BAC test and composite
score. The duration of our intervention might be one of
the reasons for negative ﬁndings, as MCCB was tested
before and after rTMS within a timeframe of 4 weeks.
This period may be too short to assess the cognitive
improvement. An intervention period of at least 6 months
is needed to detect possible changes in cognitive assess-
ments in antipsychotic trials, according to a previous
meta-analysis.43 Furthermore, the effect of practice
needs to be considered despite the high test–retest relia-
bility of the MCCB44 and two different versions were
used to assess at baseline and the end of the intervention.
The practice-related increase in cognitive performance
makes it difﬁcult to distinguish the effect of active
rTMS from the reduction of the difference between the
active and the sham group.
The present study has several limitations. First, the
patients in this study were chronic and medicated. It is
possible that antipsychotic medication might affect cogni-
tive dysfunction. Further, given the relatively small sample
size and a high rate of shedding, the negative ﬁndings in
cognition might be due to low statistical power. Secondly,
depressive symptoms were not measured or controlled in
our study. High-frequency rTMS over the left DLPFC is
able to produce antidepressant effects, which may con-
found its beneﬁcial effect on negative symptoms of schi-
zophrenia. Taken together, early episode patients, longer
rTMS periods, different stimulation frequency or location
may have led to different results.45
Table 4 Results of the stepwise multiple regression analyses in patients
Predictor Beta p-value 95% CI
SANS reducation rate
R2=0.343; F(2,33)=7.845; p=0.002
PANSS positive −0.402 0.021 −2.807, −0.247
SANS total 0.283 0.096 −0.061, 0.711
Abbreviations: PANSS, positive and negative syndrome scale; SANS, scale for the assessment of negative symptoms.
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Conclusion
In summary, high-frequency 20 Hz rTMS stimulation over
the left DLPFC at a high stimulation intensity and a sufﬁcient
number of applied stimulating pulses may represent an effec-
tive augmentation to antipsychotics to treat the negative
symptoms of schizophrenia. Existing positive symptoms
may be an important predictor factor of the efﬁcacy of
rTMS treatment. Moreover, the results suggested that rTMS
may have differential effects on negative symptoms and
cognitive impairment in schizophrenia. The stimulation para-
meters for the treatment of negative and cognitive dysfunc-
tion may be different. Optimal rTMS parameters still need to
be explored to achieve improvement in cognitive function in
this patient population.
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